


# Reducing GLP-1 spend while driving meaningful weight loss

Published results from Rx Activate member population

**\$403 PMPM**  
estimated pharmacy savings

Driven by optimized GLP-1 utilization

Members were guided to the most appropriate care path, whether behavior change alone, GLP-1s, or lower-cost anti-obesity medications (AOMs).



● GLP-1   ● Lower cost AOM   ● Behavior change   ● GLP-1 + lower cost AOM

**Most members did not use GLP-1s**

## Managing rising GLP-1 costs with smarter, coordinated care

With GLP-1 spend reaching over \$70 billion without consistent clinical oversight, employers face growing pressure to manage cost and outcomes. Vida and Capital Rx deliver a coordinated solution that pairs personalized care with Judi®-driven medication management to promote behavior change and appropriate use of GLP-1s.



## Members achieved sustained weight loss with and without GLP-1s

> **11.6%**

weight loss at 12 months  
(GLP-1s)

> **6.0%**

weight loss at 12 months (Behavior  
change and/or low-cost medication)\*

\*clinically significant weight loss is > 5%

## High engagement without medication dependence

- Members participated in **39 lifestyle activities/month** on average
- Over ~10 months of participation

Mooney K, Munro C, Voelker L, Venkatesan A. The impact of Capital Rx's Rx Activate program in partnership with Vida on GLP-1 and anti-obesity medication utilization, weight loss, and inferred cost avoidance. AMCP Annual Meeting; 2026.

## Rx Activate member spotlight

A male in his 40s enrolled in Vida to improve his weight and diabetes management.

### "Adam's" results

↓ **30 lbs (-12.7% body weight)**

↓ **2.2 A1C points**

Achieved through personalized coaching, nutrition support, and consistent engagement.



## Ready to control costs without compromising outcomes?

Optimize GLP-1 use, reduce unnecessary spend, and deliver meaningful outcomes with Vida + Capital Rx.

▶ [Talk to our team](#)